2012, Number 3
Technological development of 0.5 % Betaxolol formulation for ophthalmological use
González CA, Márquez CT, Cazanave GD, Bellma MA, Lagarto PA, Martínez EV
Full text
Language: Spanish
References: 12
Page: 292-300
PDF size: 80.59 Kb.
ABSTRACT
Introduction: betaxolol chlorhydrate is a cardioselective adrenergic ß1 blocker that does not play a significant role as membrane stabilizer (local anesthestic) and lacks intrinsic sympathomimetic activity. It diminishes the production of aqueous humor in the eye, thus reducing the intraocular pressure to normal, either with or without glaucoma. This drug is indicated in the treatment of chronic open angle glaucoma affecting patients with ocular hypertension.Objective: to design a formulation of 0.5 % Betaxolol eye drops that meets the quality control parameters for this pharmaceutical form and that provides the desired therapeutic effect.
Methods: four technological variants were performed by adequately modifying the excipient quantities and by keeping the active principle amount, for which the composition of the leading formulation was taken into account. The aim was to select the most stable variant after 3-month follow-up. The pH and the isotonicity of the formulation were adjusted for the requirements of an ophthalmologic preparation. The isotonicity was reached with sodium chloride.
Results: the technological development of this formulation was satisfactory; the final product met all the specifications for the quality control of the product as described in USP 30. The physical, chemical and microbiological properties of the preparation remained unchanged for 24 months under storage conditions of 30.0 ± 2.0 °C.
Conclusions: the formulation of a medical eye drops containing Betaxolol chlorhydrate as active principle, meets all the quality specifications for this pharmaceutical form to treat glaucoma, which may expand the therapeutic options in Cuba.
REFERENCES